ONCOLOGY PORTFOLIO – Approved Products & Pipeline

INN /COMPOUND	CLASS	TARGET & MODALITY	SETTING
PFL-002[1]	**Targeted therapy**	Anti-c-MET antibody degrader	**NSCLC** / solid tumors with MET mutations or amplification
PFL-241[2]	**Targeted therapy**	Mutant-selective 4th generation EGFR small-molecule inhibitor	**NSCLC** with *EGFR* exon 19/21 + C797S mutations
PFL-721[2]	**Targeted therapy**	Mutant-selective EGFR-exon 20 small-molecule inhibitor	**NSCLC** with *EGFR* exon 20 insertion mutation
Exarafenib[3]	**Targeted therapy**	Pan-RAF small-molecule inhibitor	*NRAS* mutant **MELANOMA** and other *BRAF* / *NRAS* mutant solid tumors
Not disclosed[4]	**Targeted therapy**	Multiple targets	**ONCOLOGY**
Encorafenib[5]	**Targeted therapy**	BRAF inhibitor + other agents	Metastatic *BRAF*^{V600E}-mutant **CRC** in first-line treatment in combination with cetuximab and FOLFOX[6]
		BRAF inhibitor + other agents	Metastatic *BRAF*^{V600E}-mutant **CRC** after prior systemic therapy in combination with cetuximab
Encorafenib + binimetinib[5]	**Targeted therapy**	BRAF inhibitor + MEK inhibitor	Unresectable or metastatic *BRAF*^{V600}-mutant **MELANOMA**
		BRAF inhibitor + MEK inhibitor	Advanced *BRAF*^{V600E}-mutant **NSCLC**
Tabelecleucel[7]	**Cell therapy**	Allogeneic T-cell immunotherapy	Relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease **(EBV+ PTLD)** after at least one prior therapy
Neratinib[8]	**Targeted therapy**	Pan-HER inhibitor	HER2 amplified / overexpressed / HR+ early **BREAST CANCER** after adjuvant trastuzumab-based therapy less than one year ago
Vinflunine	**Chemotherapy**	Vinca Alkaloid	Advanced or metastatic transitional cell carcinoma of the **UROTHELIAL** tract as monotherapy after failure of a prior platinum-containing regimen
Vinorelbine	**Chemotherapy**	Vinca Alkaloid	Advanced **BREAST CANCER** as monotherapy or in combination with other agents
		Vinca Alkaloid	Advanced **NSCLC** as monotherapy or in combination with other chemotherapies
		Vinca Alkaloid	Adjuvant treatment of **NSCLC** in combination with platinum-based chemotherapy



*The settings refer to the therapeutic indications approved in the EU countries where the product is registered (it may differ in non EU countries). For adult patients only, except Tabelecleucel which is indicated for paediatric patients 2 years of age and older.
1.Originated by Vertical Bio AG, acquired by Pierre Fabre Laboratories. **2.**Originated by Scorpion Therapeutics acquired by Pierre Fabre Laboratories. **3.**Originated by Kinnate Biopharma Inc. Investigational Pan-RAF Inhibitor, Exarafenib, acquired by Pierre Fabre Laboratories. **4.**Discovery partnership with Vernalis Lt and RedRidge Bio.
5.Developed and launched in partnership with Array Biopharma (partnered with Pfizer since 2020). **6.**Clinical devlopment and sponsorship done solely by Pfizer. **7.**Commercialized in partnership with Atara Biotherapeutics. **8.**Commercialized in partnership with Puma Biotechnology.

This display includes ongoing clinical trials for both approved and investigational compounds. Inclusion in this display does not imply regulatory approval for all these compounds or indications.
Products should be used in accordance with their prescribing information. Information about the trials can be found at www.ClinicalTrials.gov

HQ--03-24-2400065 – V11 – Elaboration date: June 2026

LABORATOIRES
Pierre Fabre